Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Multiple Sclerosis

  Free Subscription


Articles published in J Neurol

Retrieve available abstracts of 136 articles:
HTML format
Text format



Single Articles


    May 2018
  1. MARSHALL I, Thrippleton MJ, Bastin ME, Mollison D, et al
    Characterisation of tissue-type metabolic content in secondary progressive multiple sclerosis: a magnetic resonance spectroscopic imaging study.
    J Neurol. 2018 May 30. pii: 10.1007/s00415-018-8903.
    PubMed     Text format     Abstract available


  2. YAMAGUCHI H, Sakai K, Goto Y, Yamada M, et al
    Autoimmune hepatitis induced by a single injection of interferon-beta 1a in a patient with multiple sclerosis.
    J Neurol. 2018 May 29. pii: 10.1007/s00415-018-8912.
    PubMed     Text format    


  3. SANTANGELO G, Bisecco A, Trojano L, Sacco R, et al
    Cognitive performance in multiple sclerosis: the contribution of intellectual enrichment and brain MRI measures.
    J Neurol. 2018 May 26. pii: 10.1007/s00415-018-8905.
    PubMed     Text format     Abstract available


  4. ALCALA C, Gascon F, Perez-Miralles F, Gil-Perotin S, et al
    Efficacy and safety of rituximab in relapsing and progressive multiple sclerosis: a hospital-based study.
    J Neurol. 2018 May 21. pii: 10.1007/s00415-018-8899.
    PubMed     Text format     Abstract available


    April 2018
  5. RASUL T, Frederiksen JL
    Link between overweight/obese in children and youngsters and occurrence of multiple sclerosis.
    J Neurol. 2018 Apr 26. pii: 10.1007/s00415-018-8869.
    PubMed     Text format     Abstract available


  6. TAVAZZI E, Bergsland N, Cattaneo D, Gervasoni E, et al
    Effects of motor rehabilitation on mobility and brain plasticity in multiple sclerosis: a structural and functional MRI study.
    J Neurol. 2018 Apr 7. pii: 10.1007/s00415-018-8859.
    PubMed     Text format     Abstract available


    March 2018
  7. COGHE G, Corona F, Marongiu E, Fenu G, et al
    Fatigue, as measured using the Modified Fatigue Impact Scale, is a predictor of processing speed improvement induced by exercise in patients with multiple sclerosis: data from a randomized controlled trial.
    J Neurol. 2018 Mar 24. pii: 10.1007/s00415-018-8836.
    PubMed     Text format     Abstract available


  8. NAKKEN O, Lindstrom JC, Holmoy T
    Sex ratio in multiple sclerosis mortality over 65 years; an age-period-cohort analysis in Norway.
    J Neurol. 2018 Mar 21. pii: 10.1007/s00415-018-8832.
    PubMed     Text format     Abstract available


  9. CERONIE B, Jacobs BM, Baker D, Dubuisson N, et al
    Cladribine treatment of multiple sclerosis is associated with depletion of memory B cells.
    J Neurol. 2018 Mar 17. pii: 10.1007/s00415-018-8830.
    PubMed     Text format     Abstract available


  10. LANZILLO R, Prosperini L, Gasperini C, Moccia M, et al
    A multicentRE observational analysiS of PErsistenCe to Treatment in the new multiple sclerosis era: the RESPECT study.
    J Neurol. 2018 Mar 16. pii: 10.1007/s00415-018-8831.
    PubMed     Text format     Abstract available


  11. AOYAMA S, Mori M, Uzawa A, Uchida T, et al
    Serum anti-JCV antibody indexes in Japanese patients with multiple sclerosis: elevations along with fingolimod treatment duration.
    J Neurol. 2018 Mar 12. pii: 10.1007/s00415-018-8813.
    PubMed     Text format     Abstract available


  12. DEVONSHIRE V, Phillips R, Wass H, Da Roza G, et al
    Monitoring and management of autoimmunity in multiple sclerosis patients treated with alemtuzumab: practical recommendations.
    J Neurol. 2018 Mar 10. pii: 10.1007/s00415-018-8822.
    PubMed     Text format     Abstract available


  13. HOTTENROTT T, Schorb E, Fritsch K, Dersch R, et al
    The MRZ reaction and a quantitative intrathecal IgG synthesis may be helpful to differentiate between primary central nervous system lymphoma and multiple sclerosis.
    J Neurol. 2018 Mar 6. pii: 10.1007/s00415-018-8779.
    PubMed     Text format     Abstract available


  14. LOREFICE L, Fenu G, Pitzalis R, Scalas G, et al
    Autoimmune comorbidities in multiple sclerosis: what is the influence on brain volumes? A case-control MRI study.
    J Neurol. 2018 Mar 5. pii: 10.1007/s00415-018-8811.
    PubMed     Text format     Abstract available


    February 2018
  15. BROICHER SD, Filli L, Geisseler O, Germann N, et al
    Positive effects of fampridine on cognition, fatigue and depression in patients with multiple sclerosis over 2 years.
    J Neurol. 2018 Feb 20. pii: 10.1007/s00415-018-8796.
    PubMed     Text format     Abstract available


  16. VAN DER VUURST DE VRIES RM, Mescheriakova JY, Runia TF, Siepman TAM, et al
    Smoking at time of CIS increases the risk of clinically definite multiple sclerosis.
    J Neurol. 2018 Feb 20. pii: 10.1007/s00415-018-8780.
    PubMed     Text format     Abstract available


  17. BELL JS, Spencer JI, Yates RL, DeLuca GC, et al
    The cortical blood-brain barrier in multiple sclerosis: a gateway to progression?
    J Neurol. 2018 Feb 13. pii: 10.1007/s00415-017-8727.
    PubMed     Text format    


  18. ESPOSITO F, Ferre L, Clarelli F, Rocca MA, et al
    Effectiveness and baseline factors associated to fingolimod response in a real-world study on multiple sclerosis patients.
    J Neurol. 2018 Feb 12. pii: 10.1007/s00415-018-8791.
    PubMed     Text format     Abstract available


  19. ARNETH B
    Up-to-date knowledge about the association between multiple sclerosis and the reactivation of human endogenous retrovirus infections.
    J Neurol. 2018 Feb 8. pii: 10.1007/s00415-018-8783.
    PubMed     Text format     Abstract available


  20. SOLARO C, Cella M, Signori A, Martinelli V, et al
    Identifying neuropathic pain in patients with multiple sclerosis: a cross-sectional multicenter study using highly specific criteria.
    J Neurol. 2018 Feb 5. pii: 10.1007/s00415-018-8758.
    PubMed     Text format     Abstract available


  21. KALRON A, Allali G, Achiron A
    Cerebellum and cognition in multiple sclerosis: the fall status matters.
    J Neurol. 2018 Feb 2. pii: 10.1007/s00415-018-8774.
    PubMed     Text format     Abstract available


  22. WINDER K, Linker RA, Seifert F, Deutsch M, et al
    Insular multiple sclerosis lesions are associated with erectile dysfunction.
    J Neurol. 2018 Feb 1. pii: 10.1007/s00415-018-8763.
    PubMed     Text format     Abstract available


  23. LANDFELDT E, Castelo-Branco A, Svedbom A, Lofroth E, et al
    The long-term impact of early treatment of multiple sclerosis on the risk of disability pension.
    J Neurol. 2018 Feb 1. pii: 10.1007/s00415-018-8764.
    PubMed     Text format     Abstract available


    January 2018
  24. FIENE M, Rufener KS, Kuehne M, Matzke M, et al
    Electrophysiological and behavioral effects of frontal transcranial direct current stimulation on cognitive fatigue in multiple sclerosis.
    J Neurol. 2018 Jan 22. pii: 10.1007/s00415-018-8754.
    PubMed     Text format     Abstract available


  25. LEAVITT VM, Tosto G, Riley CS
    Cognitive phenotypes in multiple sclerosis.
    J Neurol. 2018 Jan 22. pii: 10.1007/s00415-018-8747.
    PubMed     Text format     Abstract available


  26. DI GREGORIO M, Gaetani L, Eusebi P, Floridi P, et al
    Treatment of multiple sclerosis relapses with high-dose methylprednisolone reduces the evolution of contrast-enhancing lesions into persistent black holes.
    J Neurol. 2018 Jan 11. pii: 10.1007/s00415-017-8726.
    PubMed     Text format     Abstract available


    December 2017
  27. FRAU J, Villar LM, Sardu C, Secci MA, et al
    Intrathecal oligoclonal bands synthesis in multiple sclerosis: is it always a prognostic factor?
    J Neurol. 2017 Dec 22. pii: 10.1007/s00415-017-8716.
    PubMed     Text format     Abstract available


  28. BRENTON JN, Schreiner T, Karoscik K, Richter M, et al
    Attitudes, perceptions, and use of marijuana in youth with multiple sclerosis.
    J Neurol. 2017 Dec 22. pii: 10.1007/s00415-017-8715.
    PubMed     Text format     Abstract available


  29. SHRIBMAN S, Hasan H, Hadavi S, Giovannoni G, et al
    The BRAIN test: a keyboard-tapping test to assess disability and clinical features of multiple sclerosis.
    J Neurol. 2017 Dec 4. pii: 10.1007/s00415-017-8690.
    PubMed     Text format     Abstract available


    November 2017
  30. THALER C, Faizy TD, Sedlacik J, Bester M, et al
    The use of multiparametric quantitative magnetic resonance imaging for evaluating visually assigned lesion groups in patients with multiple sclerosis.
    J Neurol. 2017 Nov 20. doi: 10.1007/s00415-017-8683.
    PubMed     Text format     Abstract available


  31. CONRADSSON D, Ytterberg C, von Koch L, Johansson S, et al
    Changes in disability in people with multiple sclerosis: a 10-year prospective study.
    J Neurol. 2017 Nov 20. doi: 10.1007/s00415-017-8676.
    PubMed     Text format     Abstract available


  32. ELIASDOTTIR O, Hildeman A, Longfils M, Nerman O, et al
    A nationwide survey of the influence of month of birth on the risk of developing multiple sclerosis in Sweden and Iceland.
    J Neurol. 2017 Nov 20. doi: 10.1007/s00415-017-8665.
    PubMed     Text format     Abstract available


  33. RUPRECHT K, Wildemann B, Jarius S
    Low intrathecal antibody production despite high seroprevalence of Epstein-Barr virus in multiple sclerosis: a review of the literature.
    J Neurol. 2017 Nov 2. doi: 10.1007/s00415-017-8656.
    PubMed     Text format     Abstract available


    October 2017
  34. COMI G, Patti F, Rocca MA, Mattioli FC, et al
    Efficacy of fingolimod and interferon beta-1b on cognitive, MRI, and clinical outcomes in relapsing-remitting multiple sclerosis: an 18-month, open-label, rater-blinded, randomised, multicentre study (the GOLDEN study).
    J Neurol. 2017 Oct 23. doi: 10.1007/s00415-017-8642.
    PubMed     Text format     Abstract available


  35. PARDO G, Jones DE
    Correction to: The sequence of disease-modifying therapies in relapsing multiple sclerosis: safety and immunologic considerations.
    J Neurol. 2017 Oct 23. doi: 10.1007/s00415-017-8633.
    PubMed     Text format     Abstract available


    September 2017
  36. LOREFICE L, Coghe G, Fenu G, Porta M, et al
    'Timed up and go' and brain atrophy: a preliminary MRI study to assess functional mobility performance in multiple sclerosis.
    J Neurol. 2017 Sep 11. doi: 10.1007/s00415-017-8612.
    PubMed     Text format     Abstract available


  37. PARDO G, Jones DE
    The sequence of disease-modifying therapies in relapsing multiple sclerosis: safety and immunologic considerations.
    J Neurol. 2017 Sep 6. doi: 10.1007/s00415-017-8594.
    PubMed     Text format     Abstract available


    August 2017
  38. LATTANZI S, Danni M, Taffi R, Cerqua R, et al
    Persistence to oral disease-modifying therapies in multiple sclerosis patients.
    J Neurol. 2017 Aug 22. doi: 10.1007/s00415-017-8595.
    PubMed     Text format     Abstract available


  39. HRASTELJ J, Robertson N
    Genetics of disease severity in multiple sclerosis, Alzheimer's disease, and Huntington's disease: rejuvenating genome-wide association studies.
    J Neurol. 2017 Aug 7. doi: 10.1007/s00415-017-8584.
    PubMed     Text format    


    July 2017
  40. EICHINGER P, Wiestler H, Zhang H, Biberacher V, et al
    A novel imaging technique for better detecting new lesions in multiple sclerosis.
    J Neurol. 2017 Jul 29. doi: 10.1007/s00415-017-8576.
    PubMed     Text format     Abstract available


    June 2017
  41. HAGSTROM IT, Schneider R, Bellenberg B, Salmen A, et al
    Relevance of early cervical cord volume loss in the disease evolution of clinically isolated syndrome and early multiple sclerosis: a 2-year follow-up study.
    J Neurol. 2017 Jun 9. doi: 10.1007/s00415-017-8537.
    PubMed     Text format     Abstract available


    May 2017
  42. BRITZE J, Pihl-Jensen G, Frederiksen JL
    Retinal ganglion cell analysis in multiple sclerosis and optic neuritis: a systematic review and meta-analysis.
    J Neurol. 2017 May 31. doi: 10.1007/s00415-017-8531.
    PubMed     Text format     Abstract available


  43. DIBLEY L, Coggrave M, McClurg D, Woodward S, et al
    "It's just horrible": a qualitative study of patients' and carers' experiences of bowel dysfunction in multiple sclerosis.
    J Neurol. 2017 May 26. doi: 10.1007/s00415-017-8527.
    PubMed     Text format     Abstract available


  44. FOULON S, Maura G, Dalichampt M, Alla F, et al
    Prevalence and mortality of patients with multiple sclerosis in France in 2012: a study based on French health insurance data.
    J Neurol. 2017 May 17. doi: 10.1007/s00415-017-8513.
    PubMed     Text format     Abstract available


  45. LATTANZI S, Cagnetti C, Danni M, Provinciali L, et al
    Oral and intravenous steroids for multiple sclerosis relapse: a systematic review and meta-analysis.
    J Neurol. 2017 May 10. doi: 10.1007/s00415-017-8505.
    PubMed     Text format     Abstract available


    April 2017
  46. HARDING K, Tilling K, MacIver C, Willis M, et al
    Seasonal variation in multiple sclerosis relapse.
    J Neurol. 2017 Apr 19. doi: 10.1007/s00415-017-8485.
    PubMed     Text format     Abstract available


  47. SARTORI A, Abdoli M, Freedman MS
    Can we predict benign multiple sclerosis? Results of a 20-year long-term follow-up study.
    J Neurol. 2017 Apr 17. doi: 10.1007/s00415-017-8487.
    PubMed     Text format     Abstract available


  48. HAINLINE C, Rizzo JR, Hudson TE, Dai W, et al
    Capturing saccades in multiple sclerosis with a digitized test of rapid number naming.
    J Neurol. 2017 Apr 7. doi: 10.1007/s00415-017-8484.
    PubMed     Text format     Abstract available


    March 2017
  49. PREZIOSA P, Martinelli V, Ferre L, Guaschino C, et al
    Moyamoya disease mimicking the first attack of multiple sclerosis.
    J Neurol. 2017 Mar 17. doi: 10.1007/s00415-017-8458.
    PubMed     Text format    


  50. MCLAUCHLAN D, Robertson NP
    B cell treatments for multiple sclerosis.
    J Neurol. 2017 Mar 4. doi: 10.1007/s00415-017-8442.
    PubMed     Text format    


  51. KHAN F, Amatya B, Galea MP, Gonzenbach R, et al
    Neurorehabilitation: applied neuroplasticity.
    J Neurol. 2017;264:603-615.
    PubMed     Text format     Abstract available


    February 2017
  52. DULAU C, Deloire M, Diaz H, Saubusse A, et al
    Social cognition according to cognitive impairment in different clinical phenotypes of multiple sclerosis.
    J Neurol. 2017 Feb 20. doi: 10.1007/s00415-017-8417.
    PubMed     Text format     Abstract available


  53. NIJ BIJVANK JA, Balk LJ, Tan HS, Uitdehaag BM, et al
    A rare cause for visual symptoms in multiple sclerosis: posterior internuclear ophthalmoplegia of Lutz, a historical misnomer.
    J Neurol. 2017 Feb 13. doi: 10.1007/s00415-017-8412.
    PubMed     Text format    


  54. MALONEY E, Molloy A, Al Hussona M, O'Donnell L, et al
    Natalizumab-associated progressive multifocal leukoencephalopathy: successful treatment without plasma exchange and its associated risks.
    J Neurol. 2017;264:401-403.
    PubMed     Text format    


    December 2016
  55. HYNCICOVA E, Vyhnalek M, Kalina A, Martinkovic L, et al
    Cognitive impairment and structural brain changes in patients with clinically isolated syndrome at high risk for multiple sclerosis.
    J Neurol. 2016 Dec 27. doi: 10.1007/s00415-016-8368.
    PubMed     Text format     Abstract available


  56. JARIUS S, Eichhorn P, Franciotta D, Petereit HF, et al
    The MRZ reaction as a highly specific marker of multiple sclerosis: re-evaluation and structured review of the literature.
    J Neurol. 2016 Dec 22. doi: 10.1007/s00415-016-8360.
    PubMed     Text format     Abstract available


  57. BRECKWOLDT MO, Gradl J, Hahnel S, Hielscher T, et al
    Increasing the sensitivity of MRI for the detection of multiple sclerosis lesions by long axial coverage of the spinal cord: a prospective study in 119 patients.
    J Neurol. 2016.
    PubMed     Text format     Abstract available


  58. HUSS AM, Halbgebauer S, Ockl P, Trebst C, et al
    Importance of cerebrospinal fluid analysis in the era of McDonald 2010 criteria: a German-Austrian retrospective multicenter study in patients with a clinically isolated syndrome.
    J Neurol. 2016;263:2499-2504.
    PubMed     Text format     Abstract available


    November 2016
  59. BLOCK VJ, Lizee A, Crabtree-Hartman E, Bevan CJ, et al
    Continuous daily assessment of multiple sclerosis disability using remote step count monitoring.
    J Neurol. 2016.
    PubMed     Text format     Abstract available


  60. BLASCO MR, Ramos A, Malo CG, Garcia-Merino A, et al
    Acute pneumonitis and pericarditis related to alemtuzumab therapy in relapsing-remitting multiple sclerosis.
    J Neurol. 2016.
    PubMed     Text format    


  61. SCHWARTZBACH CJ, Grove RA, Brown R, Tompson D, et al
    Lesion remyelinating activity of GSK239512 versus placebo in patients with relapsing-remitting multiple sclerosis: a randomised, single-blind, phase II study.
    J Neurol. 2016.
    PubMed     Text format     Abstract available


  62. PROSPERINI L, Sacca F, Cordioli C, Cortese A, et al
    Real-world effectiveness of natalizumab and fingolimod compared with self-injectable drugs in non-responders and in treatment-naive patients with multiple sclerosis.
    J Neurol. 2016.
    PubMed     Text format     Abstract available


  63. KOSMIDOU M, Katsanos AH, Katsanos KH, Kyritsis AP, et al
    Multiple sclerosis and inflammatory bowel diseases: a systematic review and meta-analysis.
    J Neurol. 2016.
    PubMed     Text format     Abstract available


  64. HAVLA J, Kumpfel T, Schinner R, Spadaro M, et al
    Myelin-oligodendrocyte-glycoprotein (MOG) autoantibodies as potential markers of severe optic neuritis and subclinical retinal axonal degeneration.
    J Neurol. 2016.
    PubMed     Text format     Abstract available


    October 2016
  65. DRESSLER D, Bhidayasiri R, Bohlega S, Chahidi A, et al
    Botulinum toxin therapy for treatment of spasticity in multiple sclerosis: review and recommendations of the IAB-Interdisciplinary Working Group for Movement Disorders task force.
    J Neurol. 2016.
    PubMed     Text format     Abstract available


  66. VAN GEEST Q, Westerik B, van der Werf YD, Geurts JJ, et al
    The role of sleep on cognition and functional connectivity in patients with multiple sclerosis.
    J Neurol. 2016.
    PubMed     Text format     Abstract available


  67. THORMANN A, Magyari M, Koch-Henriksen N, Laursen B, et al
    Vascular comorbidities in multiple sclerosis: a nationwide study from Denmark.
    J Neurol. 2016.
    PubMed     Text format     Abstract available


  68. ABSINTA M, Reich DS, Filippi M
    Spring cleaning: time to rethink imaging research lines in MS?
    J Neurol. 2016;263:1893-902.
    PubMed     Text format     Abstract available


    September 2016
  69. OWEN PICKRELL W, Robertson NP
    Stem cell treatment for multiple sclerosis.
    J Neurol. 2016.
    PubMed     Text format    


  70. MAILAND MT, Frederiksen JL
    Vaccines and multiple sclerosis: a systematic review.
    J Neurol. 2016.
    PubMed     Text format     Abstract available


  71. MAILLART E, Papeix C, Mellerio C, Bertrand A, et al
    Extensive and severe CNS demyelination associated with golimumab therapy.
    J Neurol. 2016;263:1869-71.
    PubMed     Text format    


    August 2016
  72. EL AYOUBI NK, Ghassan S, Said M, Allam J, et al
    Retinal measures correlate with cognitive and physical disability in early multiple sclerosis.
    J Neurol. 2016.
    PubMed     Text format     Abstract available


  73. MOBERG JY, Magyari M, Koch-Henriksen N, Thygesen LC, et al
    Educational achievements of children of parents with multiple sclerosis: A nationwide register-based cohort study.
    J Neurol. 2016.
    PubMed     Text format     Abstract available


  74. ZURAWSKI J, Flinn A, Sklover L, Sloane JA, et al
    Relapse frequency in transitioning from natalizumab to dimethyl fumarate: assessment of risk factors.
    J Neurol. 2016;263:1511-7.
    PubMed     Text format     Abstract available


    July 2016
  75. ZIEMSSEN T, Phillips G, Shah R, Mathias A, et al
    Development of the multiple sclerosis (MS) early mobility impairment questionnaire (EMIQ).
    J Neurol. 2016.
    PubMed     Text format     Abstract available


  76. BALK LJ, Cruz-Herranz A, Albrecht P, Arnow S, et al
    Timing of retinal neuronal and axonal loss in MS: a longitudinal OCT study.
    J Neurol. 2016;263:1323-31.
    PubMed     Text format     Abstract available


  77. HAVRDOVA E, Belova A, Goloborodko A, Tisserant A, et al
    Activity of secukinumab, an anti-IL-17A antibody, on brain lesions in RRMS: results from a randomized, proof-of-concept study.
    J Neurol. 2016;263:1287-95.
    PubMed     Text format     Abstract available


    June 2016
  78. PRIETO-MORIN C, Ayrignac X, Ellie E, Tournier-Lasserve E, et al
    CSF1R-related leukoencephalopathy mimicking primary progressive multiple sclerosis.
    J Neurol. 2016.
    PubMed     Text format    


  79. D'AMICO E, Leone C, Zanghi A, Fermo SL, et al
    Lateral and escalation therapy in relapsing-remitting multiple sclerosis: a comparative study.
    J Neurol. 2016.
    PubMed     Text format     Abstract available


  80. KALRON A, Givon U
    Gait characteristics according to pyramidal, sensory and cerebellar EDSS subcategories in people with multiple sclerosis.
    J Neurol. 2016.
    PubMed     Text format     Abstract available


  81. NEWSOME SD, Kieseier BC, Arnold DL, Shang S, et al
    Subgroup and sensitivity analyses of annualized relapse rate over 2 years in the ADVANCE trial of peginterferon beta-1a in patients with relapsing-remitting multiple sclerosis.
    J Neurol. 2016.
    PubMed     Text format     Abstract available


  82. JONGEN PJ, Stavrakaki I, Voet B, Hoogervorst E, et al
    Patient-reported adverse effects of high-dose intravenous methylprednisolone treatment: a prospective web-based multi-center study in multiple sclerosis patients with a relapse.
    J Neurol. 2016.
    PubMed     Text format     Abstract available


  83. MICLEA A, Leussink VI, Hartung HP, Gold R, et al
    Safety and efficacy of dimethyl fumarate in multiple sclerosis: a multi-center observational study.
    J Neurol. 2016.
    PubMed     Text format     Abstract available


  84. IAFFALDANO P, Viterbo RG, Trojano M
    Natalizumab discontinuation is associated with a rebound of cognitive impairment in multiple sclerosis patients.
    J Neurol. 2016.
    PubMed     Text format     Abstract available


    May 2016
  85. BEER A, Biberacher V, Schmidt P, Righart R, et al
    Tissue damage within normal appearing white matter in early multiple sclerosis: assessment by the ratio of T1- and T2-weighted MR image intensity.
    J Neurol. 2016.
    PubMed     Text format     Abstract available


  86. SCHIPPLING S, O'Connor P, Knappertz V, Pohl C, et al
    Incidence and course of depression in multiple sclerosis in the multinational BEYOND trial.
    J Neurol. 2016.
    PubMed     Text format     Abstract available


  87. DAVION JB, Cambron M, Duhin E, Chouraki A, et al
    Two cases of relapses in primary progressive multiple sclerosis after fingolimod withdrawal.
    J Neurol. 2016.
    PubMed     Text format     Abstract available


  88. AMANN M, Pezold S, Naegelin Y, Fundana K, et al
    Reliable volumetry of the cervical spinal cord in MS patient follow-up data with cord image analyzer (Cordial).
    J Neurol. 2016.
    PubMed     Text format     Abstract available


    April 2016
  89. MCCARTHY C, Thorpe J
    Some recent advances in multiple sclerosis.
    J Neurol. 2016.
    PubMed     Text format     Abstract available


  90. GAETANI L, Mignarri A, Di Gregorio M, Sarchielli P, et al
    Multiple sclerosis and chronic progressive external ophthalmoplegia associated with a large scale mitochondrial DNA single deletion.
    J Neurol. 2016.
    PubMed     Text format    


  91. DE KOUCHKOVSKY I, Fieremans E, Fleysher L, Herbert J, et al
    Quantification of normal-appearing white matter tract integrity in multiple sclerosis: a diffusion kurtosis imaging study.
    J Neurol. 2016.
    PubMed     Text format     Abstract available


  92. GROTHE M, Lotze M, Langner S, Dressel A, et al
    The role of global and regional gray matter volume decrease in multiple sclerosis.
    J Neurol. 2016.
    PubMed     Text format     Abstract available


  93. SANDROFF BM, Schwartz CE, DeLuca J
    Measurement and maintenance of reserve in multiple sclerosis.
    J Neurol. 2016.
    PubMed     Text format     Abstract available


  94. FAISSNER S, Nikolayczik J, Chan A, Hellwig K, et al
    Plasmapheresis and immunoadsorption in patients with steroid refractory multiple sclerosis relapses.
    J Neurol. 2016.
    PubMed     Text format     Abstract available


  95. TALLANTYRE EC, Robertson NP
    Continuous evolution of magnetic resonance imaging in multiple sclerosis.
    J Neurol. 2016.
    PubMed     Text format    


    March 2016
  96. HALBGEBAUER S, Huss A, Buttmann M, Steinacker P, et al
    Detection of intrathecal immunoglobulin G synthesis by capillary isoelectric focusing immunoassay in oligoclonal band negative multiple sclerosis.
    J Neurol. 2016.
    PubMed     Text format     Abstract available


  97. HUSSAIN R, O'Leary S, Pacheco FM, Zacharias TE, et al
    Acute relapse after initiation of Siponimod in a patient with secondary progressive MS.
    J Neurol. 2016;263:606-10.
    PubMed     Text format     Abstract available


  98. FILIPPI M, Barker RA, Strupp M
    The neurology community mourns the passing of Dr. John F. Kurtzke.
    J Neurol. 2016;263:421.
    PubMed     Text format    


    February 2016
  99. BUTTERWORTH SE, Ingram G, Robertson NP
    Advances in biomarker research in multiple sclerosis.
    J Neurol. 2016.
    PubMed     Text format    


  100. BARNETT MH, McLeod JG, Hammond SR, Kurtzke JF, et al
    Migration and multiple sclerosis in immigrants from United Kingdom and Ireland to Australia: a reassessment. III: risk of multiple sclerosis in UKI immigrants and Australian-born in Hobart, Tasmania.
    J Neurol. 2016.
    PubMed     Text format     Abstract available


  101. ZIEMSSEN T, Calabrese P, Penner IK, Apfel R, et al
    QualiCOP: real-world effectiveness, tolerability, and quality of life in patients with relapsing-remitting multiple sclerosis treated with glatiramer acetate, treatment-naive patients, and previously treated patients.
    J Neurol. 2016.
    PubMed     Text format     Abstract available


  102. LADWIG A, Dunkl V, Richter N, Schroeter M, et al
    Two cases of multiple sclerosis manifesting after in vitro fertilization procedures.
    J Neurol. 2016.
    PubMed     Text format    


  103. BARGAGLI AM, Colais P, Agabiti N, Mayer F, et al
    Prevalence of multiple sclerosis in the Lazio region, Italy: use of an algorithm based on health information systems.
    J Neurol. 2016.
    PubMed     Text format     Abstract available


  104. MATAS E, Bau L, Martinez-Iniesta M, Romero-Pinel L, et al
    Absence of MxA induction is related to a poor clinical response to interferon beta treatment in multiple sclerosis patients.
    J Neurol. 2016.
    PubMed     Text format     Abstract available


  105. ORTIZ-PEREZ S, Andorra M, Sanchez-Dalmau B, Torres-Torres R, et al
    Visual field impairment captures disease burden in multiple sclerosis.
    J Neurol. 2016.
    PubMed     Text format     Abstract available


  106. JEFFERY DR, Di Cantogno EV, Ritter S, Meier DP, et al
    The relationship between the rate of brain volume loss during first 24 months and disability progression over 24 and 48 months in relapsing MS.
    J Neurol. 2016;263:299-305.
    PubMed     Text format     Abstract available


    January 2016
  107. DOTY RL, Tourbier IA, Pham DL, Cuzzocreo JL, et al
    Taste dysfunction in multiple sclerosis.
    J Neurol. 2016.
    PubMed     Text format     Abstract available


  108. KIM G, Tauhid S, Dupuy SL, Tummala S, et al
    An MRI-defined measure of cerebral lesion severity to assess therapeutic effects in multiple sclerosis.
    J Neurol. 2016.
    PubMed     Text format     Abstract available


  109. BOVE R, McHenry A, Hellwig K, Houtchens M, et al
    Multiple sclerosis in men: management considerations.
    J Neurol. 2016.
    PubMed     Text format     Abstract available


  110. JURYNCZYK M, Weinshenker B, Akman-Demir G, Asgari N, et al
    Status of diagnostic approaches to AQP4-IgG seronegative NMO and NMO/MS overlap syndromes.
    J Neurol. 2016;263:140-9.
    PubMed     Text format     Abstract available


    December 2015
  111. ZIEMSSEN T, Derfuss T, de Stefano N, Giovannoni G, et al
    Optimizing treatment success in multiple sclerosis.
    J Neurol. 2015.
    PubMed     Text format     Abstract available


  112. KAPPOS L, Radue EW, Chin P, Ritter S, et al
    Onset of clinical and MRI efficacy occurs early after fingolimod treatment initiation in relapsing multiple sclerosis.
    J Neurol. 2015.
    PubMed     Text format     Abstract available


  113. BRAUNE S, Lang M, Bergmann A
    Efficacy of fingolimod is superior to injectable disease modifying therapies in second-line therapy of relapsing remitting multiple sclerosis.
    J Neurol. 2015.
    PubMed     Text format     Abstract available


    November 2015
  114. SALZER J, Lycke J, Wickstrom R, Naver H, et al
    Rituximab in paediatric onset multiple sclerosis: a case series.
    J Neurol. 2015.
    PubMed     Text format     Abstract available


    October 2015
  115. HEALY S, Willis MD, Robertson NP
    Prognosis in multiple sclerosis and the unveiling of pathogenic clues.
    J Neurol. 2015.
    PubMed     Text format    


  116. WINDER K, Seifert F, Koehn J, Deutsch M, et al
    Site and size of multiple sclerosis lesions predict enhanced or decreased female orgasmic function.
    J Neurol. 2015.
    PubMed     Text format     Abstract available


  117. ROSJO E, Steffensen LH, Jorgensen L, Lindstrom JC, et al
    Vitamin D supplementation and systemic inflammation in relapsing-remitting multiple sclerosis.
    J Neurol. 2015.
    PubMed     Text format     Abstract available


    September 2015
  118. MONTALBAN X, Comi G, Antel J, O'Connor P, et al
    Long-term results from a phase 2 extension study of fingolimod at high and approved dose in relapsing multiple sclerosis.
    J Neurol. 2015.
    PubMed     Text format     Abstract available


    August 2015
  119. GAETANI L, Menduno PS, Cometa F, Di Gregorio M, et al
    Retinopathy during interferon-beta treatment for multiple sclerosis: case report and review of the literature.
    J Neurol. 2015.
    PubMed     Text format     Abstract available


  120. LEOCANI L, Nuara A, Houdayer E, Schiavetti I, et al
    Sativex and clinical-neurophysiological measures of spasticity in progressive multiple sclerosis.
    J Neurol. 2015.
    PubMed     Text format     Abstract available


  121. LAMPERT EJ, Andorra M, Torres-Torres R, Ortiz-Perez S, et al
    Color vision impairment in multiple sclerosis points to retinal ganglion cell damage.
    J Neurol. 2015.
    PubMed     Text format     Abstract available


  122. COGHE G, Pau M, Corona F, Frau J, et al
    Walking improvements with nabiximols in patients with multiple sclerosis.
    J Neurol. 2015.
    PubMed     Text format     Abstract available


    July 2015
  123. LEAVITT VM, De Meo E, Riccitelli G, Rocca MA, et al
    Elevated body temperature is linked to fatigue in an Italian sample of relapsing-remitting multiple sclerosis patients.
    J Neurol. 2015.
    PubMed     Text format     Abstract available


  124. TAUHID S, Chu R, Sasane R, Glanz BI, et al
    Brain MRI lesions and atrophy are associated with employment status in patients with multiple sclerosis.
    J Neurol. 2015.
    PubMed     Text format     Abstract available


  125. KINGWELL E, Zhu F, Marrie RA, Fisk JD, et al
    High incidence and increasing prevalence of multiple sclerosis in British Columbia, Canada: findings from over two decades (1991-2010).
    J Neurol. 2015.
    PubMed     Text format     Abstract available


    June 2015
  126. JICK SS, Li L, Falcone GJ, Vassilev ZP, et al
    Epidemiology of multiple sclerosis: results from a large observational study in the UK.
    J Neurol. 2015.
    PubMed     Text format     Abstract available


  127. VIDAL-JORDANA A, Sastre-Garriga J, Rovira A, Montalban X, et al
    Treating relapsing-remitting multiple sclerosis: therapy effects on brain atrophy.
    J Neurol. 2015.
    PubMed     Text format     Abstract available


  128. ALLART E, Benoit A, Blanchard-Dauphin A, Tiffreau V, et al
    Sustained-released fampridine in multiple sclerosis: effects on gait parameters, arm function, fatigue, and quality of life.
    J Neurol. 2015.
    PubMed     Text format     Abstract available


  129. AMANN M, Papadopoulou A, Andelova M, Magon S, et al
    Magnetization transfer ratio in lesions rather than normal-appearing brain relates to disability in patients with multiple sclerosis.
    J Neurol. 2015.
    PubMed     Text format     Abstract available


    May 2015
  130. KOUDRIAVTSEVA T, Plantone D, Renna R, Inglese M, et al
    Brain perfusion by arterial spin labeling MRI in multiple sclerosis.
    J Neurol. 2015.
    PubMed     Text format    


  131. SOLA-VALLS N, Blanco Y, Sepulveda M, Llufriu S, et al
    Walking function in clinical monitoring of multiple sclerosis by telemedicine.
    J Neurol. 2015.
    PubMed     Text format     Abstract available


  132. SACCO R, Bisecco A, Corbo D, Della Corte M, et al
    Cognitive impairment and memory disorders in relapsing-remitting multiple sclerosis: the role of white matter, gray matter and hippocampus.
    J Neurol. 2015.
    PubMed     Text format     Abstract available


    February 2015
  133. KAUFMAN M, Cree BA, De Seze J, Fox RJ, et al
    Radiologic MS disease activity during natalizumab treatment interruption: findings from RESTORE.
    J Neurol. 2015;262:326-36.
    PubMed     Text format     Abstract available


    January 2015
  134. JONKMAN LE, Soriano AL, Amor S, Barkhof F, et al
    Can MS lesion stages be distinguished with MRI? A postmortem MRI and histopathology study.
    J Neurol. 2015;262:1074-80.
    PubMed     Text format     Abstract available


  135. LAUDA F, Fangerau T, Javaheripour-Otto K, Pinkhardt E, et al
    Natalizumab-associated cerebellar PML: a case report on how to slow down IRIS.
    J Neurol. 2015;262:1055-7.
    PubMed     Text format    


    August 2014
  136. MALMESTROM C, Andersson BA, Lycke J
    First reported case of diabetes mellitus type 1 as a possible secondary autoimmune disease following alemtuzumab treatment in MS.
    J Neurol. 2014.
    PubMed     Text format    


Thank you for your interest in scientific medicine.


AMEDEO Multiple Sclerosis is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: